Clinical Trial Update: A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique. [Phase 4]

View source ↗

Summary

This Phase 4 post-market study evaluates adverse event incidence in patients with skin of color undergoing correction of nasolabial folds with Hylaform, Hylafor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Facial Wrinkles

Drugs mentioned

• Captique
• Hylaform
• Hylaform Plus

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Facial Wrinkles | Phase 4 | Status: COMPLETED